Increased α-tubulin1b expression indicates poor prognosis and resistance to chemotherapy in hepatocellular carcinoma

Digestive Diseases and Sciences

Volumn 58, Issue 9, 2013, Pages 2713-2720

  Lu, Cuihua ^a   Zhang, Jing ^a   He, Song ^a   Wan, Chunhua ^a   Shan, Aidong ^a   Wang, Yingying ^a   Yu, Litao ^a   Liu, Guoliang ^a   Chen, Ken ^a   Shi, Jing ^a   Zhang, Yixin ^a   Ni, Runzhou ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Tubulin1b (TUBA1B); Chemotherapy; Hepatocellular carcinoma; Ki 67; Prognosis

Indexed keywords

ALPHA TUBULIN; ALPHA TUBULIN 1B; CHOLECYSTOKININ OCTAPEPTIDE; KI 67 ANTIGEN; PACLITAXEL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL ASSAY; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SECTION; WESTERN BLOTTING;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; TUBULIN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84884208999     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2692-z     Document Type: Article

References (29)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Cho SJ, Kim YJ, Surh YJ, Kim BM, Lee SK. Ibulocydine is a novel prodrug cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells. J Biol Chem. 2011;286:19662-19671.
3. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol. 1997;8:117-136.
4. Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials1. Radiology. 2002;224:47-54.
5. Kim ND, Park ES, Kim YH, et al. Structure-based virtual screening of novel tubulin inhibitors and their characterization as anti-mitotic agents. Bioorgan Med Chem. 2010;18:7092-7100.
6. Chen TH, Pan SL, Guh JH, et al. Moscatilin induces apoptosis in human colorectal cancer cells: a crucial role of c-jun nh2-terminal protein kinase activation caused by tubulin depolymerization and DNA damage. Clin Cancer Res. 2008;14:4250-4258.
7. Glotzer M. The 3 ms of central spindle assembly: microtubules, motors and maps. Nat Rev Mol Cell Biol. 2009;10:9-20.
8. Cheung CHA, Wu SY, Lee TR, et al. Cancer cells acquire mitotic drug resistance properties through beta i-tubulin mutations and alterations in the expression of beta-tubulin isotypes. PLoS ONE. 2010;5:e12564.
9. Hage-Sleiman R, Herveau S, Matera EL, Laurier JF, Dumontet C. Tubulin binding cofactor c (tbcc) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells. BMC Cancer. 2010;10:135.
10. Gan PP, McCarroll JA, Byrne FL, Garner J, Kavallaris M. Specific beta-tubulin isotypes can functionally enhance or diminish epothilone b sensitivity in non-small cell lung cancer cells. PLoS ONE. 2011;6:e21717.
11. Tseng CY, Mane JY, Winter P, et al. Research quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives. Mol Cancer. 2010;9:131.
12. Kohno K, Kikuchi J, Sato S, et al. Vincristine-resistant human cancer kb cell line and increased expression of multidrug-resistance gene. Cancer Sci. 1988;79:1238-1246.
13. Mechetner E, Kyshtoobayeva A, Zonis S, et al. Levels of multidrug resistance (mdr1) p-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res. 1998;4:389-398.
14. Hari M, Wang Y, Veeraraghavan S, Cabral F. Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther. 2003;2:597-605.
15. Ohishi Y, Oda Y, Basaki Y, et al. Expression of beta-tubulin isotypes in human primary ovarian carcinoma. Gynecol Oncol. 2007;105:586-592.
16. Koh Y, Jang B, Han SW, et al. Expression of class iii beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol. 2010;5:320-325.
17. Lobert S, Jefferson B, Morris K. Regulation of beta-tubulin isotypes by micro-rna 100 in mcf7 breast cancer cells. Cytoskeleton (Hoboken). 2011;68:355-362.
18. Kaira K, Serizawa M, Koh Y, et al. Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and beta iii-tubulin in thymic epithelial tumors. J Thorac Oncol. 2011;6:606-613.
19. Cho EH, Whipple RA, Matrone MA, Balzer EM, Martin SS. Delocalization of gamma-tubulin due to increased solubility in human breast cancer cell lines. Cancer Biol Ther. 2010;9:66-76.
20. Nikas JB, Boylan KLM, Skubitz APN, Low WC. Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer. Cancer Inf. 2011;10:233-247.
21. Takano T, Hasegawa Y, Miyauchi A, et al. Overexpression of kalpha1 tubulin mrna in thyroid anaplastic carcinoma. Cancer Lett. 2001;168:51-55.
22. Wang Y, Yang S, Ni Q, et al. Overexpression of forkhead box j2 can decrease the migration of breast cancer cells. J Cell Biochem. 2012;113:2729-2737.
23. Schibler MJ, Cabral F. Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha-and beta-tubulin. J Cell Biochem. 1986;102:1522-1531.
24. Kaibori M, Tanigawa N, Kariya S, et al. A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma. Dig Dis Sci. 2012;57:1404-1412.
25. Ke Q, Ji J, Cheng C, et al. Expression and prognostic role of spy1 as a novel cell cycle protein in hepatocellular carcinoma. Exp Mol Pathol. 2009;87:167-172.
26. Blenk S, Engelmann JC, Pinkert S, et al. Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis. BMC Cancer. 2008;8:106.
27. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007;43:979-992.
28. Sanchez-Perez T, Ortiz-Ferron G, Lopez-Rivas A. Mitotic arrest and jnk-induced proteasomal degradation of flip and mcl-1 are key events in the sensitization of breast tumor cells to trail by antimicrotubule agents. Cell Death Differ. 2009;17:883-894.
29. Kamino H, Moore R, Negishi M. Role of a novel car-induced gene, tuba8, in hepatocellular carcinoma cell lines. Cancer Genet. 2011;204:382-391.